The Limitations of AMD Trials

Systematic review finds AMD trials still struggle to capture what matters to patients

1

Visual acuity is insufficient to capture the full impact of age-related macular degeneration (AMD) on patients' lives.
2

A systematic review assessed the use of vision-related patient-reported outcome measures (PROMs) in randomized controlled trials (RCTs) for AMD.
3

The review identified 38 RCTs from 2001 to 2024, highlighting the dominance of the NEI VFQ-25 among the 11 PROM instruments used.
4

Baseline PROM reporting varied by AMD stage, with lower scores observed in neovascular AMD trials compared to early and intermediate stages.
5

The authors recommend a minimum reporting set for PROMs in future AMD trials to enhance the interpretation of patient experiences.

1